LA JOLLA, Calif., Feb. 16, 2017 /PRNewswire/ -- Regulus
Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company
leading the discovery and development of innovative medicines
targeting microRNAs, today announced that Nature
Communications has published an article entitled "microRNA-17
family promotes polycystic kidney disease progression through the
modulation of mitochondrial metabolism." The article highlights
research that identifies miR-17 as a target for the treatment of
autosomal dominant polycystic kidney disease (ADPKD) and can be
found on-line at http://www.nature.com/ncomms.
"This successful collaboration between Regulus scientists and
academic investigators, most importantly, Dr. Vishal Patel and his team at UT Southwestern
Medical Center, represents a major advance in our understanding of
the pathophysiology of ADPKD. These results provide strong
evidence that targeting miR-17 may provide therapeutic benefit in
humans and supports our development program for RGLS4326
(anti-miR-17) for the treatment of ADPKD," said Dr. Timothy Wright, Regulus' Chief R&D Officer.
"Regulus expects to file an IND for RGLS4326 in the second
half of 2017."
About Autosomal Dominant Polycystic Kidney Disease
(ADPKD)
ADPKD, caused by the mutations of PKD1 or PKD2, is among the
most common monogenetic disorders and a leading genetic cause of
end-stage renal disease. The clinical hallmark of this disease is
the presence of numerous renal tubule-derived cysts.
Excessive proliferation, a central pathological feature, fuels the
relentless expansion of cysts, ultimately causing end-stage renal
disease. ADPKD affects approximately 600,000 people in the US and
12.5 million people worldwide.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company leading the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a well-balanced microRNA therapeutics pipeline complemented by a
rich intellectual property estate to retain its leadership in the
microRNA field. Regulus is advancing several programs in
renal, hepatic and central nervous systems diseases, both
independently and with our strategic alliance partners, Sanofi and
AstraZeneca. Regulus maintains its corporate headquarters in
La Jolla, CA. For more
information, please visit http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the expected ability
of Regulus to undertake certain activities and accomplish certain,
the projected timeline of clinical development activities, and
expectations regarding future therapeutic and commercial potential
of Regulus' business plans, technologies and intellectual property
related to microRNA therapeutics and biomarkers being discovered
and developed by Regulus. Because such statements are subject
to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics,
and in the endeavor of building a business around such drugs.
These and other risks concerning Regulus' financial position and
programs are described in additional detail in Regulus filings with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Regulus undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/regulus-announces-publication-in-nature-communications-identifying-mir-17-as-a-promising-drug-target-for-adpkd-300408511.html
SOURCE Regulus Therapeutics Inc.